Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study

Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study

The cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) palbociclib is administered orally and cyclically, causing medication adherence challenges. We evaluated components of adherence to palbociclib, its relationship with pharmacokinetics (PK), and drug-induced neutropenia. Patients with metastatic bre...

Full description

Bibliographic Details
Main Authors: Carole Bandiera, Isabella Locatelli, Perrine Courlet, Evelina Cardoso, Khalil Zaman, Athina Stravodimou, Ana Dolcan, Apostolos Sarivalasis, Jean-Philippe Zurcher, Veronica Aedo-Lopez, Jennifer Dotta-Celio, Solange Peters, Monia Guidi, Anna Dorothea Wagner, Chantal Csajka, Marie P. Schneider
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Cancers
Subjects:
CDK4/6 inhibitor
palbociclib
neutropenia
medication adherence
electronic adherence monitoring
motivational interviewing
Online Access:https://www.mdpi.com/2072-6694/15/1/316

Internet

https://www.mdpi.com/2072-6694/15/1/316

Similar Items